MENS: Jyong Biotech Forward Price-to-Revenue Multiple

Public company logo of Jyong Biotech Corp (MENS)

Jyong Biotech Ltd (MENS) develops safe plant-based urological treatments, which forms the basis of its price action. The forward price-to-sales ratio reflects market expectations, where determines the latest valuation metric. Volatility depends on FDA approvals and cost controls, while stable raw material supply chains preclude operational disruptions in the production of biologics.

MENS Jyong Biotech: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/16/2026

Analytical breakdowns and data insights for company Jyong Biotech (MENS)

- market price and analyst price targets:
- market capitalization information:
Summary company analysis:Jyong Biotech Corp MENS
Product sample of jyongbio.com

The stable R&D workforce at Jyong Biotech Ltd (MENS) provides the foundation for future sales realization, which is directly reflected in the calculation of the forward price-to-sales multiple. By analyzing the forward P/S ratio, investors assess current market capitalization relative to expected revenue, determining the extent to which the stock's market value is justified by the potential for commercializing developments amid slowing business activity.

Who Jyong Biotech Ltd competes with

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Expected Sales Ratio Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Projected Revenue Ratio|Perrigo Company PLC - Forward Price to Sales|Price-to-Projected Revenue Ratio alvotech.com|Forward P/S Multiple Liquidia Technologies|Price-to-Projected Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Future Price to Revenue|Forward P/S Multiple MNKD (MannKind Corp)|Market Cap to Expected Sales Ratio Amphastar (AMPH)|PCRX: Forward Price-to-Revenue Multiple|SPRY - Forward P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Projected Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Projected Revenue Ratio|SCPH (scpharmaceuticals.com) - Forward P/S Multiple|TECX: Forward Price to Sales|Price-to-Projected Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Forward Price to Sales BHST|Invizyne Technologies - Forward P/S Multiple|oramed.com (ORMP) - Forward Price-to-Revenue Multiple|ENTX (enterabio.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue HYFT|ABVC (ABVC BioPharma, Inc) - Forward P/S Multiple|Forward P/S Multiple cumberlandpharma.com|Price-to-Projected Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Projected Price to Revenue|Forward P/S Multiple TELO (telomirpharma.com)|RANI - Forward Price-to-Revenue Multiple|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP